Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
about
First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyAchievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Key issues in inhibitor management in patients with haemophilia.Prophylaxis in real life scenarios.Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesProphylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.Bullous pemphigoid associated with acquired hemophilia a: a rare association of autoimmune disease.Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.How I treat inhibitors in haemophilia.Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII.
P2860
Q30832356-E5E17EDF-8A12-4D26-8A06-99DC87C8CF31Q33608230-18390D94-31FA-46AF-AA0E-3565815B74EAQ34416394-C0B77A5A-2B84-431B-860F-ABD1A58FEBF8Q37185097-A5EDEED5-9464-4ED5-ACC7-C288A80388F1Q37602415-C488B8A1-AD06-466A-9589-2E9895FB5718Q38206859-67775D66-B0DB-4DE3-B90B-F99CA3A95F62Q38235951-4796D51C-49B1-4E32-8974-4C460A1363EAQ38325328-81F8FC31-CF11-4672-A355-65B76639FB53Q41099388-3940E152-F44F-4A9B-845D-A8C717CBE2A9Q42692841-0907E024-64A4-4165-B750-F293FFFA3115Q45863328-DF516002-A205-420E-895A-13DD79CAFBA1Q45869111-CAA05AB5-3675-4BA4-BFA3-D209006B9C1BQ45877797-F88B99B0-C8A7-483D-B9CC-4D65C3D6B92AQ45879927-BA8DAF08-7732-4A61-81D5-E3B708C66A5DQ45882018-6BC74293-CE8A-405F-97AF-4DB920A54ACF
P2860
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
@en
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
@nl
type
label
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
@en
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
@nl
prefLabel
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
@en
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
@nl
P2860
P1433
P1476
Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
@en
P2093
L A Valentino
P2860
P304
P356
10.1111/J.1365-2516.2009.02126.X
P577
2009-12-16T00:00:00Z